<DOC>
	<DOCNO>NCT00289978</DOCNO>
	<brief_summary>This study assess efficacy , safety , tolerability 2 dose oral fingolimod ( 1.25 mg/day 0.5 mg/day ) compare placebo patient relapsing-remitting multiple sclerosis ( RRMS )</brief_summary>
	<brief_title>Efficacy Safety Fingolimod Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Male female patient age 1855 diagnosis multiple sclerosis Patients relapsingremitting disease course Patients EDSS score 05.5 Patients chronic disease immune system , malignancy , acute pulmonary disease , cardiac failure , etc . Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>FTY720</keyword>
	<keyword>Fingolimod</keyword>
</DOC>